Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity
Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity
复制标题
基于欧氏距离的拉曼光谱（EDRS）用于胃癌预后分析：肿瘤异质性的解决方案
DOI：
10.1016/j.saa.2022.122163
复制
发表时间：
2022-11-30
影响因子：
4.4
通讯作者：
Zhang，Huan
中科院分区：
文献类型：
--
作者：
Wang，Wenfang;Shi，Bowen;Zhang，Huan
胃癌的预后分析对选择治疗方案和开发先进的治疗方法至关重要。准确、快速、方便和低成本的胃癌预后方法是非常需要的。拉曼光谱是一种无标记和非破坏性的技术，可提供生物样品的分子指纹，有望用于癌症预后。然而，胃癌预后的主要挑战在于广泛存在的肿瘤异质性，这导致一种类型的样品内的意想不到的光谱变化。本研究将基于欧氏距离（艾德）的拉曼光谱（EDRS）方法应用于胃癌的预后分析，以消除肿瘤异质性的影响。首次在石蜡保存的胃癌患者肿瘤组织切片上采集了拉曼光谱。然后建立代表“最差预后肿瘤细胞”的标准谱。用艾德法评价各组织光谱与标准光谱的相似性，为预后提供直接的评价。我们成功地将患者分为预后不良和预后良好组，根据平均区域艾德值（灵敏度为75%，特异性为96.8%），或根据患者水平的最小艾德值（灵敏度为90%，特异性为100%）。还对EDRS进行了生存分析（AUC = 0.955），远优于常用的新辅助治疗后（ypTNM）类别（AUC = 0.718）。我们的工作突出了EDRS作为异质性癌症相关预后评估和生存预测的快速，准确，低成本和强大的工具，为光谱肿瘤分析提供了新的见解。
The prognosis analysis of gastric cancer is critical for selection of treatments and development of advanced therapeutic methods. A prognosis approach that is accurate, fast, convenient, and of low cost for gastric cancers is in high demand. Raman spectroscopy is a label-free and non-destructive technique to provide molecular fingerprints of biological samples, holding promises for cancer prognosis. However, the major challenge of gastric cancer prognosis lies in the widely existing tumor heterogeneity, which leads to unexpected spectral variations within one type of samples. In this work, we have developed the Euclidean distance (ED)-based Raman spectroscopy (EDRS) method for the prognosis analysis of gastric cancer to eliminate the influence of tumor heterogeneity. Raman spectra were first collected on the slices of paraffin-preserved tumor tissues from gastric cancer patients. A standard spectrum to represent the ‘worst prognostic tumor cells’ was then established. The similarity between each spectrum of tissues and the standard spectrum was assessed by ED, to provide a direct assessment on the prognosis status. We have successfully classified the patients into poor and favorable prognosis groups, either based on the averaged regional ED values (sensitivity of 75 %, specificity of 96.8 %), or based on the minimal ED values at the patient level (sensitivity of 90 %, specificity of 100 %). EDRS was also investigated for survival analysis (AUC = 0.955), much better than the commonly applied post-neoadjuvant therapy (ypTNM) category (AUC = 0.718). Our work highlights EDRS as a rapid, accurate, low-cost and robust tool for heterogeneous cancer-related prognosis assessment and survival prediction, providing new insights for spectroscopic tumor analysis.